Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Anti-inflammatory profile studied in preclinical models
Reconstitution method, solvent choice, and storage duration after reconstitution are protocol-specific decisions that fall to the individual researcher and their institutions standard operating procedures
All Reta products are intended strictly for research and laboratory use only and are not intended for human consumption
| 2026 | Int J Mol Sci Authors Note
US$ 28.68
US$ 26.30
US$ 25.03
